Predictors of SARS-CoV-2 Infection and Severe and Lethal COVID-19 after Three Years of Follow-Up: A Population-Wide Study.

Maria Elena Flacco, Cecilia Acuti Martellucci, Graziella Soldato, Giuseppe Di Martino, Annalisa Rosso, Roberto Carota, Marco De Benedictis, Graziano Di Marco, Rossano Di Luzio, Matteo Ricci, Antonio Caponetti, Davide Gori, Lamberto Manzoli
Author Information
  1. Maria Elena Flacco: Department of Environmental and Preventive Sciences, University of Ferrara, 44121 Ferrara, Italy. ORCID
  2. Cecilia Acuti Martellucci: Department of Environmental and Preventive Sciences, University of Ferrara, 44121 Ferrara, Italy. ORCID
  3. Graziella Soldato: Local Health Unit of Pescara, 65124 Pescara, Italy.
  4. Giuseppe Di Martino: Local Health Unit of Pescara, 65124 Pescara, Italy. ORCID
  5. Annalisa Rosso: Department of Environmental and Preventive Sciences, University of Ferrara, 44121 Ferrara, Italy. ORCID
  6. Roberto Carota: Local Health Unit of Pescara, 65124 Pescara, Italy.
  7. Marco De Benedictis: Local Health Unit of Pescara, 65124 Pescara, Italy.
  8. Graziano Di Marco: Local Health Unit of Pescara, 65124 Pescara, Italy.
  9. Rossano Di Luzio: Local Health Unit of Pescara, 65124 Pescara, Italy.
  10. Matteo Ricci: Department of Medical and Surgical Sciences, University of Bologna, 40100 Bologna, Italy. ORCID
  11. Antonio Caponetti: Local Health Unit of Pescara, 65124 Pescara, Italy.
  12. Davide Gori: Department of Medical and Surgical Sciences, University of Bologna, 40100 Bologna, Italy. ORCID
  13. Lamberto Manzoli: Department of Medical and Surgical Sciences, University of Bologna, 40100 Bologna, Italy. ORCID

Abstract

In this cohort study, the general population of an Italian Province was followed for three years after the start of the pandemic, in order to identify the predictors of SARS-CoV-2 infection and severe or lethal COVID-19. All the National Healthcare System information on biographical records, vaccinations, SARS-CoV-2 swabs, COVID-19 cases, hospitalizations and co-pay exemptions were extracted from 25 February 2020 to 15 February 2023. Cox proportional hazard analysis was used to compute the relative hazards of infection and severe or lethal COVID-19, adjusting for age, gender, vaccine status, hypertension, diabetes, major cardiovascular diseases (CVD), chronic obstructive pulmonary disease (COPD), kidney disease or cancer. Among the 300,079 residents or domiciled citizens, 41.5% had ≥1 positive swabs during the follow-up (which lasted a mean of 932 days). A total of 3.67% of the infected individuals experienced severe COVID-19 ( = 4574) and 1.76% died ( = 2190). Females, the elderly and subjects with diabetes, CVD, COPD, kidney disease and cancer showed a significantly higher risk of SARS-CoV-2 infection. The likelihood of severe or lethal COVID-19 was >90% lower among the youngest, and all comorbidities were independently associated with a higher risk (ranging from +28% to +214%) of both outcomes. Two years after the start of the immunization campaign, the individuals who received ≥2 doses of COVID-19 vaccines still showed a significantly lower likelihood of severe or lethal disease, with the lowest risk observed among subjects who received at least one booster dose.

Keywords

References

  1. Front Public Health. 2022 May 02;10:884121 [PMID: 35586006]
  2. J Public Health (Oxf). 2022 Dec 1;44(4):e475-e478 [PMID: 34492110]
  3. Lancet. 2022 Mar 5;399(10328):924-944 [PMID: 35202601]
  4. Front Public Health. 2023 Jun 01;11:1165611 [PMID: 37325336]
  5. Vaccines (Basel). 2022 Dec 23;11(1): [PMID: 36679876]
  6. J Evid Based Med. 2023 Jun;16(2):166-177 [PMID: 37186434]
  7. J Med Virol. 2022 Nov;94(11):5336-5344 [PMID: 35854433]
  8. PLoS One. 2020 Jun 24;15(6):e0235248 [PMID: 32579597]
  9. J Med Virol. 2023 Feb;95(2):e28522 [PMID: 36691933]
  10. J Intern Med. 2022 Nov;292(5):829-836 [PMID: 35943414]
  11. Cell. 2020 May 28;181(5):1036-1045.e9 [PMID: 32416070]
  12. N Engl J Med. 2022 Jan 13;386(2):116-127 [PMID: 34942067]
  13. Viruses. 2021 Mar 19;13(3): [PMID: 33808867]
  14. Vaccines (Basel). 2022 Apr 22;10(5): [PMID: 35632418]
  15. Vaccines (Basel). 2023 May 22;11(5): [PMID: 37243115]
  16. N Engl J Med. 2022 Apr 21;386(16):1532-1546 [PMID: 35249272]
  17. Vaccines (Basel). 2021 Jun 10;9(6): [PMID: 34200538]
  18. Eur Heart J. 2020 May 14;41(19):1810-1817 [PMID: 32388565]
  19. Eur J Epidemiol. 2022 Mar;37(3):235-249 [PMID: 35306604]
  20. J Prev Med Hyg. 2023 May 16;64(1):E3-E8 [PMID: 37293451]
  21. Front Med (Lausanne). 2022 Nov 09;9:1023507 [PMID: 36438045]
  22. J Med Virol. 2022 Jun;94(6):2837-2844 [PMID: 35118680]
  23. Front Cell Infect Microbiol. 2021 Oct 25;11:674277 [PMID: 34760713]
  24. Vaccines (Basel). 2023 Aug 04;11(8): [PMID: 37631893]
  25. Lancet Reg Health Eur. 2023 May;28:100614 [PMID: 37131863]
  26. J Infect Dis. 2021 Feb 13;223(3):362-369 [PMID: 33119738]
  27. Eur Respir J. 2023 Jul 7;62(1): [PMID: 37419522]
  28. JAMA Pediatr. 2021 Feb 1;175(2):143-156 [PMID: 32975552]
  29. Biomed Rep. 2022 May;16(5):34 [PMID: 35386106]
  30. J Infect Dis. 2023 May 12;227(10):1164-1172 [PMID: 36729177]
  31. Eur J Clin Invest. 2022 Oct;52(10):e13845 [PMID: 35904405]
  32. Biomedicines. 2022 Sep 29;10(10): [PMID: 36289699]
  33. Rev Med Virol. 2021 Jan;31(1):1-10 [PMID: 32845042]
  34. J Med Virol. 2022 Jul;94(7):2969-2976 [PMID: 35246846]
  35. Eur Respir J. 2023 Jul 7;62(1): [PMID: 37080568]
  36. PLoS One. 2020 Nov 17;15(11):e0241955 [PMID: 33201896]
  37. Eur Respir Rev. 2022 Nov 2;31(166): [PMID: 36323422]
  38. BMJ Glob Health. 2021 Dec;6(12): [PMID: 34916273]

Word Cloud

Created with Highcharts 10.0.0COVID-19SARS-CoV-2severelethaldiseaseriskinfectioncohortstudyyearsstartpredictorsswabsFebruarydiabetesCVDCOPDkidneycancerindividuals=subjectsshowedsignificantlyhigherlikelihoodloweramongreceivedgeneralpopulationItalianProvincefollowedthreepandemicorderidentifyNationalHealthcareSysteminformationbiographicalrecordsvaccinationscaseshospitalizationsco-payexemptionsextracted252020152023CoxproportionalhazardanalysisusedcomputerelativehazardsadjustingagegendervaccinestatushypertensionmajorcardiovasculardiseaseschronicobstructivepulmonaryAmong300079residentsdomiciledcitizens415%≥1positivefollow-uplastedmean932daystotal367%infectedexperienced4574176%died2190Femaleselderly>90%youngestcomorbiditiesindependentlyassociatedranging+28%+214%outcomesTwoimmunizationcampaign≥2dosesvaccinesstilllowestobservedleastoneboosterdosePredictorsInfectionSevereLethalThreeYearsFollow-Up:Population-WideStudyItalyfactors

Similar Articles

Cited By